116 related articles for article (PubMed ID: 23011550)
1. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up.
Saboo SS; Zukotynski K; Shinagare AB; Krajewski KM; Ramaiya N
Abdom Imaging; 2013 Aug; 38(4):728-35. PubMed ID: 23011550
[TBL] [Abstract][Full Text] [Related]
2. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis.
Jones M; Hruby G; Solomon M; Rutherford N; Martin J
Ann Surg Oncol; 2015 Oct; 22(11):3574-81. PubMed ID: 25652048
[TBL] [Abstract][Full Text] [Related]
3. Assessing the impact of FDG-PET in the management of anal cancer.
Nguyen BT; Joon DL; Khoo V; Quong G; Chao M; Wada M; Joon ML; See A; Feigen M; Rykers K; Kai C; Zupan E; Scott A
Radiother Oncol; 2008 Jun; 87(3):376-82. PubMed ID: 18453023
[TBL] [Abstract][Full Text] [Related]
4. Role of positron emission tomography-computed tomography in the management of anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
[TBL] [Abstract][Full Text] [Related]
5. Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
Piperkova E; Raphael B; Altinyay M; Castellon I; Libes R; Sandella N; Abdel-Dayem H
J BUON; 2006; 11(4):523-7. PubMed ID: 17309188
[TBL] [Abstract][Full Text] [Related]
6. Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
Iagaru A; Kundu R; Jadvar H; Nagle D
Hell J Nucl Med; 2009; 12(1):26-9. PubMed ID: 19330178
[TBL] [Abstract][Full Text] [Related]
7. PET/CT in anal cancer - is it worth doing?
Wells IT; Fox BM
Clin Radiol; 2012 Jun; 67(6):535-40. PubMed ID: 22208962
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity.
Pasha MA; Marcus C; Fakhry C; Kang H; Kiess AP; Subramaniam RM
AJR Am J Roentgenol; 2015 Aug; 205(2):W150-61. PubMed ID: 26001119
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
10. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT in the evaluation of anal carcinoma.
Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
15. Clinical values of (18) F-FDG PET/CT in oral cavity cancer with dental artifacts on CT or MRI.
Hong HR; Jin S; Koo HJ; Roh JL; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2014 Nov; 110(6):696-701. PubMed ID: 24995957
[TBL] [Abstract][Full Text] [Related]
16. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
17. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
Schwarz JK; Siegel BA; Dehdashti F; Myerson RJ; Fleshman JW; Grigsby PW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):180-6. PubMed ID: 17996387
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT in the management of colorectal and anal cancers.
Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
[TBL] [Abstract][Full Text] [Related]
19. F-18 FDG PET/CT imaging of anal canal squamous cell carcinoma.
Nguyen BD; Ram PC; Roarke MC
Clin Nucl Med; 2007 Mar; 32(3):234-6. PubMed ID: 17314608
[No Abstract] [Full Text] [Related]
20. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
